A Phase 2 interventional study of Lenalidomide in Myelodysplastic Syndromes, sponsored by Celgene. Completed at 6 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-11-19.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing lenalidomide in Myelodysplastic Syndromes — none open to participants now, none under way, none of them phase 3. Lenalidomide · Myelodysplastic Syndromes.
Among the 44 studies testing lenalidomide in Myelodysplastic Syndromes, this one is the 33rd largest by enrollment of the 43 interventional ones that give a count, is the only one that started in 2007, is one of 24 in phase 2, and was the 12th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →None of the 44 studies testing lenalidomide in Myelodysplastic Syndromes is open now. The open studies under Myelodysplastic Syndromes, anywhere →
Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 31 · Phase 3 3
First in 2002; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 32 across the 43 interventional studies. Of the 38 that completed or were terminated, 21 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb: 4 open now, 9 under way, 5 of them phase 3. Of 63 finished, 20 (32%) have results posted.
Among the 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb, this one is the 43rd largest by enrollment of the 46 interventional ones that give a count, is one of 5 that started in 2007, is one of 14 in phase 2, and was the 19th registered.
Bristol-Myers Squibb’s Myelodysplastic Syndromes studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing lenalidomide in Myelodysplastic Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 75 in Myelodysplastic Syndromes:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical experience study is to determine whether CC-5013 is safe and effective (to include studying the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body [pharmacokinetics]) in Japanese subjects with low- or intermediate-1-risk MDS (IPSS risk categories) associated with a deletion 5(q31-33) abnormality and symptomatic anemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).
Drug: Lenalidomide
Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).
Also known as: CC-5013
Number of Participants With Adverse Events (AE)
An AE that resulted in any of the following outcomes was defined as a serious adverse event (SAE): * Death; * Life-threatening event; * Any inpatient hospitalization or prolongation of existing hospitalization; * Persistent or significant disability or incapacity; * Congenital anomaly or birth defect; * Any other important medical event. The investigator determined the relationship of an AE to study drug based on the timing of the AE relative to drug administration and whether or not other drugs, therapeutic interventions, or underlying conditions could provide a sufficient explanation for the event. The severity of an AE was evaluated by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 3.0) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death.
Time frame: After the first study dose until 28 days after completion of/discontinuation from the study (maximum time on study was 155 weeks).
Maximum Observed Plasma Concentration (Cmax) of Lenalidomide
Maximum observed plasma concentration of lenalidomide after a single dose on Day and after multiple doses (Day 4).
Time frame: Days 1 and 4 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours post-dose.
Time to Maximum Plasma Concentration (Tmax) of Lenalidomide
Time to maximum observed plasma concentration of lenalidomide after a single dose on Day 1 and multiple doses (Day 4).
Time frame: Days 1 and 4 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours post-dose.
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Lenalidomide
Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUCt) of lenalidomide after a single dose on Day 1 and multiple doses (Day 4).
Time frame: Days 1 and 4 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours post-dose.
Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCτ) of Lenalidomide
Area under the plasma concentration-time curve over the dosing interval (AUCτ) of lenalidomide after a single dose on Day 1 and multiple doses (Day 4).
Time frame: Days 1 and 4 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12 and 24 hours post-dose.
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Lenalidomide
Area under the plasma concentration-time curve from time zero to infinity (AUC∞) of lenalidomide after a single dose on Day 1.
Time frame: Day 1 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12 and 24 hours post-dose.
Terminal Half-life (T1/2) of Lenalidomide
The apparent terminal half-life is the time required for plasma concentration to decrease by 50% after pseudo-equilibrium of distribution has been reached, and calculated as the natural logarithm of 2 (0.693) / Apparent terminal rate constant (λz).
Time frame: Days 1 and 4 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours post-dose.
Apparent Volume of Distribution (VzF) of Lenalidomide
Apparent volume of distribution of lenalidomide after a single dose on Day 1 and multiple doses (Day 4).
Time frame: Days 1 and 4 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours post-dose.
Apparent Total Plasma Clearance (CL/F) of Lenalidomide
Apparent total plasma clearance (CL/F) of lenalidomide after a single dose on Day 1 and multiple doses (Day 4).
Time frame: Days 1 and 4 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours post-dose.
Apparent Terminal Elimination Rate Constant of Lenalidomide
Apparent terminal elimination rate constant of lenalidomide determined after a single dose on Day 1 and multiple doses (Day 4).
Time frame: Days 1 and 4 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours post-dose.
Number of Participants With a Erythroid Response
Erythroid response was determined using the International Working Group (IWG) 2000 criteria, categorized as a major response or minor response. A major response in patients with transfusion-dependent anemia (receiving ≥ 4.5 units of red blood cell (RBC) transfusion during 56 consecutive days at Baseline) is defined as RBC transfusion independence accompanied by a ≥1.0 g/dL increase from Baseline in hemoglobin sustained for 56 days consecutively during the treatment period. In patients with transfusion-independent anemia with hemoglobin \< 10 g/dL at Baseline a major response is defined as a \> 2.0 g/dL increase from Baseline in hemoglobin sustained for consecutive 56 days. Minor response in patients with transfusion-dependent anemia defined as ≥ 50% decrease from Baseline in transfusion requirements sustained for consecutive 56 days, and in transfusion-independent patients as 1.0 to 2.0 g/dL increase from Baseline in hemoglobin sustained for consecutive 56 days.
Time frame: Response was assessed every 28 days through Week 156.
Time to Erythroid Response
Time to erythroid response was calculated as the time from the first dose of study drug to the start of the first major or minor erythroid response. Similarly, time to major erythroid response was calculated as the time from the first dose of study drug to the start of the first major erythroid response.
Time frame: From the first dose of study drug through Week 156
Duration of Erythroid Response
Duration of erythroid response was calculated as the time from the start of the first major or minor erythroid response to the end of the response. Similarly, duration of major erythroid response was calculated as the time from the start of the first major erythroid response to the end of the response. Response duration was censored at the last adequate assessment for patients who maintained response.
Time frame: From the first dose of study drug through Week 156
Change From Baseline in Hemoglobin Concentration
Change in hemoglobin concentration from Baseline to the maximum observed value during the major erythroid response period for major erythroid responders.
Time frame: Baseline and from Day1 until the maximum observed value (up to 155 weeks)
Number of Participants With a Neutrophil Response
Neutrophil response was determined using the IWG (2000) criteria. A major response for participants with a Baseline neutrophil count \< 1,500/mm\^3 is defined as a ≥ 100% increase or a ≥ 500/mm\^3 increase, whichever is greater, sustained for consecutive 56 days during the treatment period. A minor response for participants with a Baseline neutrophil count \< 1,500/mm\^3 is defined as a ≥ 100% increase, but an absolute increase \< 500/mm\^3, sustained for consecutive 56 days during the treatment period.
Time frame: Response was assessed every 28 days through Week 156
Number of Participants With a Platelet Response
Platelet response was determined using the IWG (2000) criteria. Major response in patients with Baseline platelet count \< 100,000/mm\^3 is defined as a ≥ 30,000/mm\^3 increase sustained for consecutive 56 days during the treatment period. In platelet-transfusion-dependent patients at Baseline a major response is defined as stabilization of platelet counts and platelet transfusion independence sustained for consecutive 56 days during the treatment period. Minor response in patients with Baseline platelet count \< 100,000/mm\^3 is defined as a ≥ 50% increase in platelet count with an absolute increase \> 10,000/mm\^3 and \< 30,000/mm\^3 sustained for consecutive 56 days during the treatment period.
Time frame: Response was assessed every 28 days through Week 156
Number of Participants With a Cytogenetic Response
Cytogenetic (chromosome structure) abnormalities were assessed by a central cytogenetic reviewer based on prints and cytogenetic reports of the bone marrow sample from the central laboratory. Cytogenetic response was determined using the IWG (2000) criteria and categorized as either a major response or minor response. Twenty metaphases were analyzed for the determination of cytogenetic response. A major response was defined as no detectable cytogenetic abnormality, if an abnormality was present at Baseline, sustained for consecutive 56 days during the treatment period. A minor response was defined as ≥ 50% reduction from Baseline in abnormal metaphases sustained for consecutive 56 days during the treatment period.
Time frame: Response was assessed every 12 weeks through Week 156
Change From Baseline in Percentage of Bone Marrow Erythroblasts
Bone marrow morphology was assessed by the central hematologic reviewers based on the locally-prepared bone marrow smear slide and clot section.
Time frame: Baseline, at the end of Cycle 3 (Day 85) and Cycle 6 (Day 169).
Percentage of Bone Marrow Myeloblasts
Bone marrow morphology was assessed by the central hematologic reviewers based on the locally-prepared bone marrow smear slide and clot section.
Time frame: Baseline, at the end of Cycle 3 (Day 85) and Cycle 6 (Day 169).
Percentage of Bone Marrow Promyelocytes
Bone marrow morphology was assessed by the central hematologic reviewers based on the locally-prepared bone marrow smear slide and clot section.
Time frame: Baseline, at the end of Cycle 3 (Day 85) and Cycle 6 (Day 169).
| Milestone | Lenalidomide |
|---|---|
| Started | 11 |
| Completed | 0 |
| Not completed | 11 |
| Withdrew: Relapse after erythroid response | 6 |
| Withdrew: Disease progression | 1 |
| Withdrew: No further treatment required | 1 |
| Withdrew: Study closed due to marketing approval | 3 |
An AE that resulted in any of the following outcomes was defined as a serious adverse event (SAE): * Death; * Life-threatening event; * Any inpatient hospitalization or prolongation of existing hospitalization; * Persistent or significant disability or incapacity; * Congenital anomaly or birth defect; * Any other important medical event. The investigator determined the relationship of an AE to study drug based on the timing of the AE relative to drug administration and whether or not other drugs, therapeutic interventions, or underlying conditions could provide a sufficient explanation for the event. The severity of an AE was evaluated by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 3.0) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death.
| participants | Lenalidomide |
|---|---|
| Any adverse event (AE) | 11 |
| AE related to study drug | 11 |
| Grade 3 or 4 AE | 11 |
| Grade 3 or 4 AE related to study drug | 11 |
| Serious AE (SAE) | 3 |
| SAE related to study drug | 1 |
| AE leading to discontinuation of study drug | 0 |
| Related AE leading to discontinuation | 0 |
| AE leading to a dose reduction or interruption | 10 |
| Related AE leading to dose reduction/interruption | 9 |
| Deaths | 0 |
Maximum observed plasma concentration of lenalidomide after a single dose on Day and after multiple doses (Day 4).
| ng/mL | Lenalidomide: Day 1 | Lenalidomide: Day 4 |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Lenalidomide | 136 ± 43.1 | 149 ± 31.2 |
Time to maximum observed plasma concentration of lenalidomide after a single dose on Day 1 and multiple doses (Day 4).
| hours | Lenalidomide: Day 1 | Lenalidomide: Day 4 |
|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of Lenalidomide | 2.52 (1.00 to 5.95) | 2.93 (1.00 to 4.00) |
Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUCt) of lenalidomide after a single dose on Day 1 and multiple doses (Day 4).
| ng*h/mL | Lenalidomide: Day 1 | Lenalidomide: Day 4 |
|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Lenalidomide | 718.4 ± 41.2 | 803.5 ± 46.9 |
Area under the plasma concentration-time curve over the dosing interval (AUCτ) of lenalidomide after a single dose on Day 1 and multiple doses (Day 4).
| ng*h/mL | Lenalidomide: Day 1 | Lenalidomide: Day 4 |
|---|---|---|
| Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCτ) of Lenalidomide | 866.5 ± 44.1 | 877.9 ± 43.0 |
Area under the plasma concentration-time curve from time zero to infinity (AUC∞) of lenalidomide after a single dose on Day 1.
| ng*h/mL | Lenalidomide |
|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Lenalidomide | 878.0 ± 45.1 |
The apparent terminal half-life is the time required for plasma concentration to decrease by 50% after pseudo-equilibrium of distribution has been reached, and calculated as the natural logarithm of 2 (0.693) / Apparent terminal rate constant (λz).
| hours | Lenalidomide: Day 1 | Lenalidomide: Day 4 |
|---|---|---|
| Terminal Half-life (T1/2) of Lenalidomide | 3.26 ± 23.0 | 3.57 ± 29.6 |
Apparent volume of distribution of lenalidomide after a single dose on Day 1 and multiple doses (Day 4).
| liters | Lenalidomide: Day 1 | Lenalidomide: Day 4 |
|---|---|---|
| Apparent Volume of Distribution (VzF) of Lenalidomide | 53.6 ± 30.9 | 58.6 ± 25.8 |
Apparent total plasma clearance (CL/F) of lenalidomide after a single dose on Day 1 and multiple doses (Day 4).
| mL/minute | Lenalidomide: Day 1 | Lenalidomide: Day 4 |
|---|---|---|
| Apparent Total Plasma Clearance (CL/F) of Lenalidomide | 189.8 ± 45.1 | 189.9 ± 43.0 |
Apparent terminal elimination rate constant of lenalidomide determined after a single dose on Day 1 and multiple doses (Day 4).
| 1/h | Lenalidomide: Day 1 | Lenalidomide: Day 4 |
|---|---|---|
| Apparent Terminal Elimination Rate Constant of Lenalidomide | 0.213 ± 23.0 | 0.194 ± 39.0 |
Erythroid response was determined using the International Working Group (IWG) 2000 criteria, categorized as a major response or minor response. A major response in patients with transfusion-dependent anemia (receiving ≥ 4.5 units of red blood cell (RBC) transfusion during 56 consecutive days at Baseline) is defined as RBC transfusion independence accompanied by a ≥1.0 g/dL increase from Baseline in hemoglobin sustained for 56 days consecutively during the treatment period. In patients with transfusion-independent anemia with hemoglobin \< 10 g/dL at Baseline a major response is defined as a \> 2.0 g/dL increase from Baseline in hemoglobin sustained for consecutive 56 days. Minor response in patients with transfusion-dependent anemia defined as ≥ 50% decrease from Baseline in transfusion requirements sustained for consecutive 56 days, and in transfusion-independent patients as 1.0 to 2.0 g/dL increase from Baseline in hemoglobin sustained for consecutive 56 days.
| participants | Lenalidomide |
|---|---|
| Erythroid responders (major or minor) | 11 |
| Major erythroid responders | 11 |
Time to erythroid response was calculated as the time from the first dose of study drug to the start of the first major or minor erythroid response. Similarly, time to major erythroid response was calculated as the time from the first dose of study drug to the start of the first major erythroid response.
| weeks | Lenalidomide |
|---|---|
| Time to erythroid response (major or minor) | 2.1 (0.3 to 11.1) |
| Time to major erythroid response | 6.3 (3.1 to 31.1) |
Duration of erythroid response was calculated as the time from the start of the first major or minor erythroid response to the end of the response. Similarly, duration of major erythroid response was calculated as the time from the start of the first major erythroid response to the end of the response. Response duration was censored at the last adequate assessment for patients who maintained response.
| weeks | Lenalidomide |
|---|---|
| Duration of erythroid response (major or minor) | 76.6 (8.9 to 152.0) |
| Duration of major erythroid response | 72.1 (32.1 to 144.1) |
Change in hemoglobin concentration from Baseline to the maximum observed value during the major erythroid response period for major erythroid responders.
| g/dL | Lenalidomide |
|---|---|
| Baseline concentration | 7.0 (4.7 to 9.1) |
| Maximum concentration during study | 13.1 (10.7 to 15.8) |
| Change from Baseline to maximum value | 6.0 (2.7 to 11.1) |
Neutrophil response was determined using the IWG (2000) criteria. A major response for participants with a Baseline neutrophil count \< 1,500/mm\^3 is defined as a ≥ 100% increase or a ≥ 500/mm\^3 increase, whichever is greater, sustained for consecutive 56 days during the treatment period. A minor response for participants with a Baseline neutrophil count \< 1,500/mm\^3 is defined as a ≥ 100% increase, but an absolute increase \< 500/mm\^3, sustained for consecutive 56 days during the treatment period.
| participants | Lenalidomide |
|---|---|
| Major response | 1 |
| Minor response | 0 |
Platelet response was determined using the IWG (2000) criteria. Major response in patients with Baseline platelet count \< 100,000/mm\^3 is defined as a ≥ 30,000/mm\^3 increase sustained for consecutive 56 days during the treatment period. In platelet-transfusion-dependent patients at Baseline a major response is defined as stabilization of platelet counts and platelet transfusion independence sustained for consecutive 56 days during the treatment period. Minor response in patients with Baseline platelet count \< 100,000/mm\^3 is defined as a ≥ 50% increase in platelet count with an absolute increase \> 10,000/mm\^3 and \< 30,000/mm\^3 sustained for consecutive 56 days during the treatment period.
No measurements were reported for this outcome.
Cytogenetic (chromosome structure) abnormalities were assessed by a central cytogenetic reviewer based on prints and cytogenetic reports of the bone marrow sample from the central laboratory. Cytogenetic response was determined using the IWG (2000) criteria and categorized as either a major response or minor response. Twenty metaphases were analyzed for the determination of cytogenetic response. A major response was defined as no detectable cytogenetic abnormality, if an abnormality was present at Baseline, sustained for consecutive 56 days during the treatment period. A minor response was defined as ≥ 50% reduction from Baseline in abnormal metaphases sustained for consecutive 56 days during the treatment period.
| participants | Lenalidomide |
|---|---|
| Major response | 1 |
| Minor response | 5 |
Bone marrow morphology was assessed by the central hematologic reviewers based on the locally-prepared bone marrow smear slide and clot section.
| Percentage of Bone Marrow Erythroblasts | Lenalidomide |
|---|---|
| Change from Baseline at the end of Cycle 3 | 36.5 (-12.0 to 51.0) |
| Change from Baseline at the end of Cycle 6 | 21.5 (-5.0 to 56.0) |
Bone marrow morphology was assessed by the central hematologic reviewers based on the locally-prepared bone marrow smear slide and clot section.
| Percentage of myeloblasts | Lenalidomide |
|---|---|
| Baseline (N=11) | 3.77 (1.20 to 8.40) |
| End of Cycle 3 (N=10) | 1.47 (0.01 to 4.55) |
| End of Cycle 6 (N=10) | 1.79 (0.01 to 4.00) |
Bone marrow morphology was assessed by the central hematologic reviewers based on the locally-prepared bone marrow smear slide and clot section.
| Percentage of promyelocytes | Lenalidomide |
|---|---|
| Baseline (N=11) | 5 (0 to 13) |
| End of Cycle 3 (N=10) | 5 (1 to 12) |
| End of Cycle 6 (N=10) | 5 (1 to 12) |
Collected over From the first dose of study drug through 28 days after completion of/discontinuation from the study (maximum time on study was 155 weeks).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lenalidomide | — | 3/11 (27.3%) | 11/11 (100%) |
| Event | Lenalidomide |
|---|---|
| Gastric UlcerGastrointestinal disorders | 1/11 |
| CholelithiasisHepatobiliary disorders | 1/11 |
| Herpes ZosterInfections and infestations | 1/11 |
| InfluenzaInfections and infestations | 1/11 |
| Spinal Compression FractureInjury, poisoning and procedural complications | 1/11 |
| Liver Function Test AbnormalInvestigations | 1/11 |
| AnorexiaMetabolism and nutrition disorders | 1/11 |
| Event | Lenalidomide |
|---|---|
| NeutropeniaBlood and lymphatic system disorders | 11/11 |
| ThrombocytopeniaBlood and lymphatic system disorders | 11/11 |
| LeukopeniaBlood and lymphatic system disorders | 10/11 |
| ConstipationGastrointestinal disorders | 10/11 |
| LymphopeniaBlood and lymphatic system disorders | 8/11 |
| NasopharyngitisInfections and infestations | 8/11 |
| RashSkin and subcutaneous tissue disorders | 8/11 |
| EosinophiliaBlood and lymphatic system disorders | 5/11 |
| PruritusSkin and subcutaneous tissue disorders | 5/11 |
| BasophiliaBlood and lymphatic system disorders | 4/11 |
| Age, Continuous(years) | Lenalidomide |
|---|---|
| Mean | 71.8 ± 5.95 |
| Sex: Female, Male(Participants) | Lenalidomide |
|---|---|
| Female | 7 |
| Male | 4 |
| Region of Enrollment(participants) | Lenalidomide |
|---|---|
| Japan | 11 |
| Duration of MDS(years) | Lenalidomide |
|---|---|
| Mean | 2.0 ± 1.44 |
| International Prognostic Scoring System (IPSS) Score(participants) | Lenalidomide |
|---|---|
| Low risk | 2 |
| Intermediate-1 risk | 9 |
| Intermediate-2 risk | 0 |
| High risk | 0 |
| French-American-British (FAB) classification of MDS(participants) | Lenalidomide |
|---|---|
| Refractory anemia (RA) | 9 |
| Refractory anemia with ringed sideroblasts (RARS) | 0 |
| Refractory anemia with excess blasts (RAEB) | 2 |
| Chronic myelomonocytic leukemia (CMML) | 0 |
| RAEB in transformation (RAEB-t) | 0 |
| World Health Organization Classification of MDS(participants) | Lenalidomide |
|---|---|
| Refractory anemia (RA) | 0 |
| RA with ringed sideroblasts (RARS) | 0 |
| Refractory anemia with excess blasts-1 (RAEB-1) | 2 |
| Refractory anemia with excess blasts-2 (RAEB-2) | 0 |
| Refractory cytopenia multilineage dysplasia (RCMD) | 1 |
| RCMD and ringed sideroblasts (RCMD-RS) | 0 |
| MDS, unclassified (MDS-U) | 0 |
| MDS associated with isolated del(5q) | 8 |
| Bone Marrow Cellularity(participants) | Lenalidomide |
|---|---|
| Aplastic (0%) | 0 |
| Hypocellular (> 0% to ≤ 30%) | 3 |
| Normocellular (> 30% to ≤ 60%) | 5 |
| Hypercellular (> 60% to ≤ 90%) | 2 |
| Packed (> 90% to ≤ 100%) | 0 |
| Missing | 1 |
1 further baseline measures are reported on the registry.
Ran from Sep 2007 to primary completion in Sep 2010, 36 months.
Results were first posted in Dec 2013, 3 years 3 months after primary completion.
Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 36 months is close to that.
Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenalidomide